Should a Struggling Medtech Company Get a Second Chance: Interview With IONIQ CEO Jared Bauer
October 28, 2021
IONIQ CEO, Jared Bauer – a self-described “heavy thinker” was featured in a recent episode of Medsider.
Bauer explains the two key factors he looks at when determining whether a medical device company is worth trying to turn around, why finding investors who really care about your mission is a strategic benefit, and why he hopes that IONIQ’s devices will one day have a place in your medicine cabinet.
IONIQ Sciences, using bioimpedance, is developing a device that can potentially detect cancers in early stages. The company’s device was granted a breakthrough designation for lung cancer by the FDA in 2020.
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
